Quick Answer: GLP-1 Questions to Ask Your Clinician
The best GLP-1 questions to ask your clinician are the ones that clarify why the medication is being considered, whether your medical history changes the risk-benefit balance, how side effects and monitoring will be handled, what it may cost long term, and what the plan is if you stop. GLP-1 medications are discussed most often for weight management, but some drugs in this broader medication family also have roles in type 2 diabetes care, cardiovascular risk reduction, kidney-risk reduction in people with type 2 diabetes and chronic kidney disease, and obesity-related obstructive sleep apnea, depending on the exact medication and approved indication.[1][2][3]
This checklist is designed for a clinician conversation, not self-prescribing. The right questions depend on the reason for treatment, the medication being considered, current diagnoses, pregnancy plans, medication list, insurance coverage, and side-effect risk. Some people are asking about semaglutide for weight loss, others are asking about tirzepatide, and others are discussing GLP-1 medications because of diabetes, cardiovascular, kidney, or sleep-related risk. Those are related but not identical conversations.
Professional-care note: this article is educational and does not determine whether any reader qualifies for, should start, should stop, or should switch a GLP-1 medication. These medications require individualized medical judgment. A qualified clinician should review diagnosis, medical history, medications, pregnancy status or plans, side-effect risk, monitoring needs, and access before treatment decisions are made.
The GLP-1 Question Checklist
A useful appointment does not need to start with “Can I get Ozempic?” or “Should I take semaglutide?” A clearer starting point is: “What problem are we trying to treat, and what would make this medication appropriate or inappropriate for me?” The checklist below keeps the discussion focused without turning the article into medical advice.
| Question to ask | Why it matters | Helpful follow-up |
|---|---|---|
| What are we treating: weight, type 2 diabetes, cardiovascular risk, kidney risk, sleep apnea, or more than one issue? | Different GLP-1-related medications have different approved uses, benefits, precautions, and insurance requirements.[1][2][3] | Ask which outcome will define success: weight, A1C, blood pressure, kidney markers, symptoms, medication reduction, or another goal. |
| Which medication are you considering, and why this one? | Semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide are not interchangeable, and tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a GLP-1-only drug. | Ask whether the proposed medication matches the reason for treatment and whether alternatives are reasonable to discuss. |
| How does my diagnosis, BMI category, and medical history fit the medication’s approved use or clinical rationale? | Eligibility is not only about weight. Comorbidities, diabetes status, cardiovascular history, kidney disease, sleep apnea, and prior treatment attempts may all affect the discussion. | Ask what documentation may be needed for insurance or prior authorization. |
| What medical history would make this medication risky or inappropriate? | Labels for several GLP-1-related drugs include contraindications or cautions involving medullary thyroid carcinoma or MEN2, serious hypersensitivity, pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney injury from dehydration, diabetic retinopathy, and hypoglycemia when combined with insulin or sulfonylureas.[1][2][3] | Ask which symptoms should trigger a call, urgent visit, or medication hold. |
| How should pregnancy, fertility treatment, or breastfeeding plans affect this decision? | Product labeling includes pregnancy-related cautions, and some semaglutide labeling instructs discontinuation at least 2 months before a planned pregnancy for certain indications.[1][3] | Ask about contraception, timing, and what to do if pregnancy occurs while taking medication. |
| What side effects are most likely, and how will we handle them? | Nausea, vomiting, diarrhea, constipation, abdominal pain, reflux-like symptoms, and reduced appetite are common across several labels, although frequency and severity vary by medication and person.[1][2][3] | Ask whether side effects are expected to improve, when they become concerning, and how dose changes are handled. |
| What will we monitor? | Monitoring may include weight, blood pressure, blood glucose, A1C, kidney function when dehydration risk is present, gastrointestinal symptoms, gallbladder symptoms, diabetes-retinopathy symptoms, and medication interactions. | Ask how often follow-up visits and labs should happen, especially during dose escalation. |
| How might this affect my other medications, procedures, or oral contraceptive use? | GLP-1-related medications can delay gastric emptying, which can affect some oral medications, and product labels include cautions around hypoglycemia with insulin or sulfonylureas and aspiration risk around anesthesia or deep sedation.[1][2][3] | Ask what to do before surgery, endoscopy, colonoscopy, or any planned procedure. |
| What will it cost now and later? | Coverage can depend on diagnosis, plan rules, prior authorization, shortages, pharmacy access, and whether the medication is prescribed for weight management, diabetes, or another indication. | Ask about prior authorization, refill reliability, copay changes, and the plan if coverage ends. |
| What happens if I stop? | Clinical trials show that stopping anti-obesity pharmacotherapy can be followed by weight regain in many participants, so long-term planning matters.[5][6] | Ask whether the medication is being approached as short-term, long-term, or conditional on specific goals and tolerability. |
Short Glossary: Which GLP-1 Medication Are You Discussing?
“GLP-1” is often used casually to describe several related medications, but the details matter. Some medications are GLP-1 receptor agonists. Tirzepatide is commonly grouped into GLP-1 conversations, but it is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist. Brand names, approved uses, formulations, supply, and insurance coverage can change, so the medication-specific discussion should happen with a clinician and pharmacist.
| Generic name | Medication type | Common conversation context | Question to ask |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Discussed for chronic weight management under weight-management labeling, and for type 2 diabetes, cardiovascular risk, and kidney-risk reduction under diabetes-related labeling depending on product.[1][3] | Which semaglutide product are we discussing, and what indication is it being prescribed for? |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | Discussed for weight management, type 2 diabetes, and obesity-related obstructive sleep apnea depending on product and indication.[2] | Are we discussing a weight-management product, a diabetes product, or another approved use? |
| Liraglutide | GLP-1 receptor agonist | Historically used in type 2 diabetes and chronic weight-management contexts depending on product and dose. | Why would this be preferred over a newer or different option? |
| Dulaglutide | GLP-1 receptor agonist | Usually discussed in type 2 diabetes care rather than as a primary weight-management medication. | What diabetes, cardiovascular, or medication-simplification goal is this meant to support? |
| Exenatide | GLP-1 receptor agonist | An older GLP-1 option mainly discussed in type 2 diabetes contexts; current availability may vary by product and market. | Is this medication still available and appropriate compared with other current options? |
Questions About Eligibility and Medical History
The eligibility conversation should be more specific than “Do I qualify?” A clinician needs to know the reason treatment is being considered, the relevant diagnosis, and whether medical history changes the risk-benefit balance. For weight management, that may involve BMI category and weight-related conditions. For diabetes, it may involve A1C, current medications, hypoglycemia risk, cardiovascular disease, kidney disease, and treatment goals. For sleep apnea, the discussion may involve whether obesity-related obstructive sleep apnea has been diagnosed and how medication would fit with sleep-medicine care.
Useful questions include:
- What diagnosis or risk factor makes this medication worth discussing?
- Does my medical history change the risk-benefit balance?
- Do I have any contraindications, such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2?[1][2][3]
- How should past pancreatitis, gallbladder disease, severe reflux, gastroparesis, kidney problems, or diabetic eye disease affect the plan?
- How should pregnancy plans, fertility treatment, breastfeeding, or contraception affect timing?
- Does a history of an eating disorder, restrictive eating, binge eating, or body-image distress change how we should approach this?
Those questions are not meant to rule anyone in or out from an article. They are meant to help the clinician identify what should be reviewed before prescribing. The same medication can be reasonable in one clinical context and inappropriate or risky in another.
Questions About Benefits, Goals, and Expectations
GLP-1 conversations can become confusing when the expected benefit is vague. A person discussing medication for weight management may be focused on appetite, weight trajectory, waist circumference, blood pressure, mobility, sleep apnea symptoms, or metabolic risk. A person discussing medication for type 2 diabetes may be focused on A1C, glucose variability, hypoglycemia risk, cardiovascular history, kidney disease, or simplifying a medication regimen. These goals overlap, but they are not identical.
Ask questions that make the goal measurable and medically meaningful:
- What benefit are we realistically trying to achieve?
- How long should it take before we know whether the medication is helping?
- What side effects or lack of response would make us stop, pause, or change the plan?
- How will success be measured beyond the scale?
- If I have type 2 diabetes, cardiovascular disease, chronic kidney disease, or sleep apnea, how does that change the goal?
It is also reasonable to ask how this medication fits into the broader care plan. For example, a GLP-1-related drug may be one part of care, while sleep apnea treatment, blood pressure control, lipid management, diabetes care, nutrition support, strength training, or mental-health care may remain important. Medication is not a moral shortcut, and lifestyle care is not a moral test. Both can be part of evidence-based care.
Questions About Side Effects and Monitoring
Gastrointestinal side effects are among the most common reasons people struggle with GLP-1-related medications. Product labels for semaglutide and tirzepatide list adverse reactions such as nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia or reflux-like symptoms, and other digestive symptoms.[1][2][3] The practical question is not only whether side effects can happen. It is how they will be prevented, monitored, and handled if they occur.
| Topic | Question to ask | Why it matters |
|---|---|---|
| Nausea, vomiting, diarrhea, or constipation | What symptoms are expected, what symptoms are not, and when should I call? | Severe or persistent vomiting or diarrhea can increase dehydration risk and may contribute to kidney problems in susceptible people.[1][2][3] |
| Pancreatitis symptoms | What kind of abdominal pain should be treated as urgent? | Labels warn clinicians to observe for pancreatitis symptoms such as persistent severe abdominal pain, sometimes radiating to the back and with or without vomiting.[1][2][3] |
| Gallbladder symptoms | What symptoms could suggest gallbladder disease? | Some GLP-1-related labels include warnings about acute gallbladder disease.[1][2][3] |
| Blood sugar | If I use insulin or a sulfonylurea, does the dose need review? | Hypoglycemia risk can increase when GLP-1-related medications are used with insulin or insulin secretagogues such as sulfonylureas.[1][2][3] |
| Kidney function | Should kidney function be monitored, especially if I have vomiting, diarrhea, or low fluid intake? | Labels warn about acute kidney injury, often in the setting of dehydration from gastrointestinal symptoms.[1][2][3] |
| Eye symptoms in diabetes | If I have diabetic retinopathy, how should eye symptoms or eye follow-up be handled? | Semaglutide labeling includes diabetic-retinopathy warnings in people with type 2 diabetes.[1][3] |
| Procedures and anesthesia | What should I tell my surgeon, anesthesiologist, dentist, or endoscopy team? | Several labels note delayed gastric emptying and rare postmarketing reports of pulmonary aspiration during anesthesia or deep sedation.[1][2][3] |
Monitoring should also include tolerability and follow-up access. A person may need a plan for missed doses, dose escalation, constipation, appetite changes, medication interactions, alcohol use, and what to do if side effects interfere with eating, drinking, work, caregiving, or sleep.
Questions About Cost, Access, Insurance, and Compounded Products
Cost and access are medical planning issues, not afterthoughts. A medication that works on paper may not be sustainable if insurance denies it, a prior authorization expires, the pharmacy cannot fill it reliably, or the monthly cost becomes unaffordable. This is especially relevant for weight-management prescriptions, where coverage varies widely by plan and indication.
Questions to ask before starting include:
- Will this require prior authorization, and what diagnosis or documentation is needed?
- What is the estimated monthly cost after insurance, and could that change?
- Is there a plan if the pharmacy cannot fill the medication on time?
- What happens if my insurance covers a diabetes product but not a weight-management product, or vice versa?
- If the medication is expected to be long term, what is the long-term affordability plan?
- Should I avoid certain online, compounded, or non-pharmacy sources?
Compounded products need a careful conversation. The FDA has warned about unapproved GLP-1 products marketed for weight loss and has stated that compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality in the same way approved drugs do.[7][8] The FDA has also warned about dosing errors involving compounded injectable semaglutide products.[9] A clinician or pharmacist can help assess whether a product source is legitimate, whether the formulation matches the prescription, and whether the risks are being explained accurately.
Questions About Stopping or Pausing a GLP-1 Medication
Stopping medication should be part of the first conversation, not a surprise later. In the STEP 1 semaglutide extension, participants regained a substantial portion of lost weight after stopping semaglutide and lifestyle intervention.[6] In the SURMOUNT-4 tirzepatide withdrawal trial, continuing tirzepatide helped maintain or further reduce weight, while switching to placebo after a lead-in period led to weight regain in many participants.[5]
Those trials do not predict exactly what will happen to any one person, but they do support a practical point: long-term planning matters. Ask:
- Is this being considered as long-term treatment or as a time-limited trial?
- What would make us stop: side effects, pregnancy, lack of response, cost, supply, procedure planning, or another reason?
- If I stop, what follow-up plan helps monitor weight, glucose, blood pressure, appetite, or other relevant markers?
- Should stopping be coordinated with changes in nutrition support, activity, sleep apnea care, diabetes medications, or other medications?
People should not change prescribed medication plans on their own. A prescriber can explain whether a dose should be paused, adjusted, restarted, or stopped based on symptoms, timing, procedure plans, pregnancy considerations, and access.
Lifestyle Support Questions Without Moralizing
GLP-1 care should not frame lifestyle as a test of willpower. Appetite, satiety, food noise, glucose regulation, sleep, stress, pain, mobility, medications, and socioeconomic access all influence weight and metabolic health. The practical role of lifestyle support is to protect nutrition, function, and long-term health while medication decisions are being made.
Useful questions include:
- How should I think about protein intake while appetite is lower?
- Should I add or maintain resistance training to support strength and function?
- What constipation-prevention plan is reasonable if bowel habits slow down?
- How should hydration be handled if nausea, diarrhea, or reduced intake occurs?
- Does alcohol use affect side effects, appetite, reflux, blood sugar, sleep, or safety in my case?
- Would a dietitian, diabetes educator, sleep specialist, mental-health clinician, or exercise professional be useful?
- How often should follow-up happen during dose changes?
These questions are especially important when weight loss happens quickly, appetite becomes very low, constipation develops, diabetes medications are being adjusted, or a person has a history of disordered eating. The goal is not to create a perfect routine. The goal is to make the medication plan safer, more tolerable, and better connected to the person’s actual life.
Symptoms to Ask About Promptly
Before starting, ask the clinician what symptoms should trigger a same-day call, urgent care, emergency care, or medication hold. This list is not a diagnosis tool, but it can help frame the conversation:
- Severe or persistent abdominal pain, especially pain that may radiate to the back or comes with vomiting.
- Repeated vomiting, inability to keep fluids down, signs of dehydration, or very low urine output.
- Symptoms of gallbladder disease, such as severe right-upper-abdominal pain, fever, jaundice, or persistent nausea.
- Symptoms of severe hypoglycemia, especially in people using insulin or sulfonylureas.
- Allergic-type symptoms, such as swelling of the face, lips, tongue, or throat; breathing difficulty; or widespread hives.
- New or worsening vision symptoms in people with diabetes or known diabetic retinopathy.
- Pregnancy or a plan to become pregnant while taking a medication with pregnancy-related labeling cautions.
Readers should ask their own clinician which symptoms apply to their case, because risk depends on medication, dose, medical history, other prescriptions, and the reason for treatment.
Bottom Line
A strong GLP-1 appointment is not just about asking for a medication name. It is about clarifying the reason for treatment, the exact medication being discussed, the expected benefits, the safety concerns that apply to your history, how side effects will be managed, how monitoring will work, whether the medication is affordable long term, and what the plan is if it is stopped or paused.
Weight management is the most common reason many people search for GLP-1 questions, but the conversation may also involve type 2 diabetes, cardiovascular risk, kidney risk, or obesity-related obstructive sleep apnea depending on the medication and clinical context. A qualified clinician can connect those details to the individual medical record in a way an online checklist cannot.
FAQ
What should I ask my doctor before starting semaglutide?
Ask what condition semaglutide is being considered for, which product is being discussed, whether your medical history creates cautions, what benefits are realistic, how side effects will be handled, what monitoring is needed, what it will cost, and what happens if it is stopped.
Are GLP-1 medications only for weight loss?
No. Some GLP-1-related medications are used in type 2 diabetes care, and certain products have labeling involving cardiovascular risk, kidney risk, chronic weight management, or obesity-related obstructive sleep apnea depending on the medication.[1][2][3]
Who should be cautious with GLP-1 medications?
Caution depends on the medication and the person. Ask about thyroid cancer history, MEN2, pancreatitis, gallbladder disease, kidney issues, severe gastrointestinal disease, diabetic retinopathy, pregnancy plans, eating disorder history, and interactions with diabetes medications.
What side effects should I ask about?
Ask about nausea, vomiting, diarrhea, constipation, abdominal pain, reflux-like symptoms, dehydration, pancreatitis symptoms, gallbladder symptoms, low blood sugar risk if using insulin or sulfonylureas, and what symptoms require urgent care.
What if insurance will not cover a GLP-1 medication?
Ask about prior authorization, diagnosis documentation, approved alternatives, pharmacy availability, long-term affordability, and whether any suggested source is FDA-approved and dispensed through a legitimate pharmacy.
What happens if I stop a GLP-1 medication?
Weight regain can occur after stopping anti-obesity pharmacotherapy in clinical trials, but the pattern varies. Ask your prescriber what monitoring, nutrition support, activity support, and follow-up plan would apply if medication is paused or stopped.[5][6]
References
- DailyMed. (2026). WEGOVY (semaglutide) prescribing information. U.S. National Library of Medicine.
- DailyMed. (2026). ZEPBOUND (tirzepatide) prescribing information. U.S. National Library of Medicine.
- DailyMed. (2026). OZEMPIC (semaglutide) prescribing information. U.S. National Library of Medicine.
- Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Yanovski, S. Z., Yanovski, J. A., & Acosta, A. (2022). AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology, 163(5), 1198–1225.
- Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., & SURMOUNT-4 Investigators. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48.
- Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.
- U.S. Food and Drug Administration. (2025). FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
- U.S. Food and Drug Administration. (2025). Medications containing semaglutide marketed for type 2 diabetes or weight loss.
- U.S. Food and Drug Administration. (2024). FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products.
